Repaglinide

Reagents were purchased from suppliers as indicated: Inosine (Sigma-Aldrich, St. Louis, MO); CGS15943, MRS3777, PSB36, PSB603, ZM241385, PSB0777, NECA, BAY60-6583, repaglinide, iberiotoxin and apamin (Tocris Bioscience, Minneapolis, MN). Inosine was dissolved in distilled water. CGS15943, MRS3777, PSB36, PSB603, ZM241385, PSB0777, NECA, BAY60-6583, iberiotoxin and apamin were dissolved in DMSO and repaglinide was dissolved in ethanol. Exposure of tissues to vehicle alone did not alter spontaneous activity (Supplementary Figure S2). Antagonists were equilibrated in the organ bath for 15 min before the addition of an agonist. The High Capacity Reverse Transcription kit, Universal Master Mix and gene expression assays for rat A_2A (Rn00583935_m1), A_2B (Rn00567697_m1) and GAPDH (Rn01775763_g1) were from Life Technologies (Foster City, CA).

BTC/AM was obtained from BioNordika (Herlev, Denmark). Diazoxide, levcromakalim, nateglinide, P1075, PNU-37883A, repaglinide, Y-26763, and ZM226600 were purchased from Tocris (Bristol, UK). BMS-191095, gliclazide, and glimepiride were purchased from MedChemExpress (Sollentuna, Sweden). All other chemicals were obtained from Sigma-Aldrich. Test compounds were dissolved in anhydrous DMSO to generate 10 mM stock solutions and diluted in assay buffer before use. The final concentration of DMSO used was less than or equal to 1 % (v/v).